Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: Association with mode of invasion and lymph node metastasis

Oral Oncology

Volumn 34, Issue 1, 1998, Pages 58-62

  Nozaki, S ^a   Endo, Y ^a   Kawashiri, S ^a   Nakagawa, K ^a   Yamamoto, E ^a   Yonemura, Y ^a   Sasaki, T ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Oral cancer; Plasminogen activator inhibitor 1; Plasminogen activator inhibitor 2; Urokinase type plasminogen activator; Urokinase type plasminogen activator receptor

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE;

ADULT; AGED; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METASTASIS POTENTIAL; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

EID: 0031921285     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(97)00028-6     Document Type: Article

References (25)

1. [1] Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Laboratory Investigation 1983;49:636-649.
2. [2] Fidler IJ, Gersten DW, Hart I. The biology of cancer invasion and metastasis. Advances in Cancer Research 1978;28:149-250.
3. [3] Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993;71:1368-1383.
4. [4] Danø K, Andreasen PA, Grødahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Advances in Cancer Research 1985;44:139-266.
5. [5] Pöllänen J, Stephenes RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Advances in Cancer Research 1991;57:273-328.
6. [6] Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. Journal of Cell Biology 1988;107:2437-2445.
7. [7] Ossowski L, Clunie G, Masucci T, Blasi F. In vivo paracrine interaction between urokinase and its receptor: Effect on tumor cell invasion. Journal of Cell Biology 1991;115:1107-1112.
8. [8] Kruithof EKO. Plasminogen activator inhibitors - a review. Enzyme 1988;40:113-121.
9. [9] Yamamoto E, Kohama G, Sunagawa H, Iwai M, Hiratsuka H. Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity. Cancer 1983;51:2175-2180.
10. [10] Yamamoto E, Sunakawa H, Kohama G. Clinical course of diffuse invasive carcinoma of the tongue excised after bleomycin treatment. Journal of Maxillofacial Surgery 1983;11:269-274.
11. [11] Yamamoto E, Miyakawa A, Kohama G. Mode of invasion and lymph node metastasis in squamous cell carcinoma of the oral cavity. Head and Neck Surgery 1984;6:938-947.
12. [12] Yonemura Y, Nojima N, Kaji M, et al. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma. Cancer 1995;76:941-953.
13. [13] Nozaki S, Endo Y, Chatani S, et al. Plasminogen activation system associated with invasion and metastasis of head and neck tumor. Oral Oncology 1995;31B:145-148.
14. [14] Baker MS, Bleakley P, Woodrow GC, Doe WF. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Research 1990;50:4676-4684.
15. [15] Nielsen LS, Andreasen PA, Grondahl-Hansen J, Skriver L, Danø K. Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass. FEBS Letters 1986;196:269-273.
16. [16] Noguchi-Takino M, Endo Y, Yonemura Y, Sasaki T. Relationship between expression of plasminogen activator system and metastatic ability in human cancer. International Journal of Oncology 1996;8:97-105.
17. [17] Ishikawa N, Endo Y, Sasaki T. Inverse correlation between mRNA expression of plasminogen activator inhibitor-2 and lymph node metastasis in human breast cancer. Japanese Journal of Cancer Research 1996;87:480-487.
18. [18] Cajot JF, Kruithof EKO, Schleuning WD, Sordat B, Bachmann F. Plasminogen activators, plasminogen activator inhibitors and procoagulant analysis in twenty human tumor cell lines. International Journal of Cancer 1986;38:719-727.
19. [19] Grøndahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Research 1993;53:2513-2521.
20. [20] Quax PH, Leeuwen RT. van, Verspaget HW, Verheijen JH. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines. Cancer Research 1990;50:1488-1494.
21. [21] Morodomi T, Ogata Y, Sasaguri Y, Morimatsu M, Nagase H. Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochemical Journal 1992;285:603-611.
22. [22] Nagase H, Enghild JJ, Suzuki K, Salvenson G. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin)by proteinases and (4-aminophenyl) mercuric acetate. Biochemistry 1990;29:5783-5789.
23. [23] Suzuki K, Enghild JJ, Morodomi T, Salvesen G, Nagase H. Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry 1990;29:10261-10270.
24. [24] Miyazaki K, Umenishi F, Funahashi K, Koshikawa N, Yasumitsu H, Umeda M. Activation of TIMP-2/progelatinase A complex by stromelysin. Biochemical and Biophysical Research Communications 1992;185:852-859.
25. [25] Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. Journal of Biological Chemistry 1992;267:3581-3584.